stockmarketproxy
/
ALKSNasdaq SEC EDGAR

Alkermes plc.

Pharmaceutical Preparations·DUBLIN 4, L2·FY end 12/31·CIK 1520262
OverviewFinancialsCompensationGovernanceInsidersFilings

Financials

5-year history · USD
MetricFY 2025FY 2024FY 2023FY 2022FY 2021Trend
Revenue$1.5B$1.6B$1.7B$1.1B$1.2B
Gross Profit——————
Operating Income$254.0M$420.6M$414.1M-$142.3M-$29.3M
Net Income$241.7M$367.1M$355.8M-$158.3M-$48.2M
Operating CF$520.8M$439.1M$401.4M$21.0M$101.7M
Capex$40.4M$33.5M$48.0M$38.3M$28.0M
Free Cash Flow$480.3M$405.6M$353.3M-$17.2M$73.7M
Buybacks—$200.3M————
Dividends——————
Gross Margin——————
Operating Margin17.2%27.0%24.9%-12.8%-2.5%
Net Margin16.4%23.6%21.4%-14.2%-4.1%
FCF Margin32.5%26.0%21.2%-1.5%6.3%
R&D / Revenue22.0%15.7%16.3%35.4%34.6%
Effective Tax17.1%16.1%-23.2%5.4%-22.5%
Debt / Equity——0.240.280.26
Buybacks / FCF—49.4%————

Peer comparison

Pharmaceutical Preparations · 5 peers
CEO Pay Ratio
ALKS
30:1
ROIV
518:1
AXSM
23:1
COGT
95:1
PFE
277:1
ABT
166:1
CEO total comp
ALKS
$8M
ROIV
$163M
AXSM
$34M
COGT
$28M
PFE
$28M
ABT
$24M
Net Margin
ALKS
16.4%
ROIV
-592.0%
AXSM
-28.7%
COGT
—
PFE
12.4%
ABT
14.7%